Live
- Kiran Abbavaram's Hard Work Pays Off: Bunny Vasu Lauds Ka Team at Success Meet
- PM Modi’s welfare schemes transform rural lives in Bokaro, residents share gratitude
- We will ensure Bangladeshi infiltrators are removed from Jharkhand: BJP's Gourav Vallabh
- Hezbollah fires five rockets at central, northern Israel: sources
- HM Amit Shah, Rajnath Singh to address several rallies in Jharkhand tomorrow
- Will not waste single day in getting back what we lost, Omar Abdullah tells Assembly
- PM Modi visits Advani's residence to wish him on birthday, shares special moment
- Sun-Dried Cotton to Be Taken to CCI Purchase Centers, Avoid Middlemen - Collector
- Survey Process Requires Public Cooperation - Collector Badavath Santosh
- Distribution of Maize Seeds to Farmers at Agricultural Research Center
Glenmark Pharmarolls outlow-cost drug for diabetes
Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.
Hyderabad: Glenmark Pharmaceuticals, a drug major on Thursday launched a patent protected sodium glucose co-transporter (SGLT2) inhibitor Remogliflozin etabonate (Remogliflozin) in India.
The drug is indicated in the treatment of type-2 diabetes mellitus in adults.
The drug was launched under brand names Remo and Remozen, at a price of Rs 12.50 per tablet.
The new diabetic drug, Remogliflozin, was discovered and developed by Japanese firm Kissei Pharmaceutical Co Ltd and later developed by GlaxoSmithKline plc and Glenmark collaborator BHV Pharma, a wholly owned subsidiary of North Carolina USA-based Avolynt, Inc.
The drug company expects 12 to 14 per cent growth in its India revenues during the current fiscal, Sujesh Vasudevan, President, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals said.
